[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367448-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367448-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-clinical-trial-designs-emerging-from-the-molecular-reclassification-of-cancer","Novel clinical trial designs emerging from the molecular reclassification of cancer","","Next-generation sequencing shows advanced/metastatic cancers possess complex, individualized genomic landscapes, forcing an overhaul of oncology treatment and clinical trial design. Molecular reclassification indicates outcomes are driven more by disease biology than by tissue of origin, shifting trials from tissue-specific phase studies to biomarker-driven and tissue-agnostic, and finally to patient-centered N-of-1 precision medicine. Multiomic technologies and real-world evidence, including exceptional responder analysis and synthetic arms, enable personalization, while decentralized access and AI/ML may optimize therapy and accelerate discovery.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-clinical-trial-designs-emerging-from-the-molecular-reclassification-of-cancer/367448/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-clinical-trial-designs-emerging-from-the-molecular-reclassification-of-cancer/367448.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does molecular reclassification change the goal of oncology clinical trials?","Question",{"text":63,"@type":64},"It shifts focus from tissue-of-origin evidence to the molecular underpinnings of disease, driving trial strategies that match therapies to each patient’s genomic landscape.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the progression of trial designs described in the paper?",{"text":68,"@type":64},"It moves from traditional tissue-specific phase 1/2/3 studies to biomarker-driven trials, then to tissue-agnostic (drug-centered) designs, and ultimately to patient-centered N-of-1 precision medicine trials.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are innovative technologies and real-world evidence emphasized?",{"text":72,"@type":64},"Technologies beyond genomics (such as transcriptomics, immunomics, proteomics, and others) and approaches using real-world data and patient-reported outcomes help refine therapy selection and support personalized therapeutic approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367448,1790387706,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10. 3322/caac.21880  \nREVIEW ARTICLE  \nNovel clinical trial designs emerging from the molecular reclassification of cancer  \nMina Nikanjam MD, PhD 1,2  | Shumei Kato MD1,2 | Teresa Allen BA3 | Jason K. Sicklick MD2,4,5  | Razelle Kurzrock MD6,7  \n1Division of Hematology‐Oncology, University of California San Diego, La Jolla,  \nCalifornia, USA  \n2Moores Cancer Center, University of California San Diego Health, La Jolla, California, USA  \n3Patient Author, San Diego, California, USA 4Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, California, USA  \n5Department of Pharmacology, University of California San Diego, San Diego,  \nCalifornia, USA  \n6Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA  \n7Worldwide Innovative Networking in Personalized Cancer Medicine Consortium, Paris, France  \nCorrespondence  \nMina Nikanjam, University of California San Diego, 1200 Garden View Road, Encinitas, CA 92024, USA. [Email:](Email: mnikanjam@health.ucsd.edu)[ mnikanjam@health.ucsd.edu](Email: mnikanjam@health.ucsd.edu)  \nRazelle Kurzrock, Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA.  \nEmail: [rkurzrock@mcw.edu](rkurzrock@mcw.edu)  \nFunding information  \nNational Institutes of Health, Grant/Award Numbers: 5U01CA180888‐08, 5UG1CA233198‐05  \nAbstract  \nNext‐generation sequencing has revealed the disruptive reality that advanced/ metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease, rather than the tissue of origin, that mostly drives outcomes. Consequently, oncology clinical trials have evolved from standard phase 1, 2, and 3 tissue‐specific studies; to tissue‐specific, biomarker‐driven trials; to tissue‐agnostic trials untethered from histology (all drug‐centered designs); and, ultimately, to patient‐centered, N‐of‐1 precision medicine studies in which each patient receives a personalized, biomarker‐matched therapy/combination of drugs. Innovative technologies beyond genomics, including those that address transcriptomics, immunomics, proteomics, functional impact, epigenetic changes, and metabolomics, are enabling further refinement and customization of therapy. Decentralized studies have the potential to improve access to trials and precision medicine approaches for underserved minorities. Evaluation of real‐world data, assessment of patient‐ reported outcomes, use of registry protocols, interrogation of exceptional responders, and exploitation of synthetic arms have all contributed to personalized therapeutic approaches. With greater than 1 􀀂 1012 potential patterns of genomic alterations and greater than 4.5 million possible three‐drug combinations, the deployment of artificial intelligence/machine learning may be necessary for the optimization of individual therapy and, in the near future, also may permit the discovery of new treatments in real time.  \nKEYWORDS  \ncancer, N‐of‐1, personalized medicine, precision medicine, tissue agnostic  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nINTRODUCTION  \nThere is a rapidly growing body of knowledge in cancer genomics anda more recent explosion of multiomic and functional technologies (Figure 1) that have revealed a complicated and heterogeneous molecular landscape in advanced and metastatic cancers.1 Biologic heterogeneity exists between histologies, within the same diagnostic group, and even within individual patients.2–6 Inde","cbCair6s0QvsRp8D","https://ap.wps.com/l/cbCair6s0QvsRp8D","pdf",945188,25,"English","# Introduction\n## Evolution of oncology clinical trial designs\n## Genomic and multiomic drivers of personalized therapy\n## Emerging trial endpoints and resistance mechanisms","[{\"question\":\"How does molecular reclassification change the goal of oncology clinical trials?\",\"answer\":\"It shifts focus from tissue-of-origin evidence to the molecular underpinnings of disease, driving trial strategies that match therapies to each patient’s genomic landscape.\"},{\"question\":\"What is the progression of trial designs described in the paper?\",\"answer\":\"It moves from traditional tissue-specific phase 1/2/3 studies to biomarker-driven trials, then to tissue-agnostic (drug-centered) designs, and ultimately to patient-centered N-of-1 precision medicine trials.\"},{\"question\":\"Why are innovative technologies and real-world evidence emphasized?\",\"answer\":\"Technologies beyond genomics (such as transcriptomics, immunomics, proteomics, and others) and approaches using real-world data and patient-reported outcomes help refine therapy selection and support personalized therapeutic approaches.\"}]","Novel clinical trial designs emerging from the molecular reclassification of cancer | PDF",1790170829,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48ea3d1f62fbf4e0d289b326b67d3f08.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fc4152d5d06589ab62ba8bf973647c9.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dae9f28acc0c370312fe2033bf8f9b7.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c3391ba11cbc690a35a0e1bebaece50.webp",980,1287]